Systemic Sclerosis clinical trials at UCSF
2 research studies open to eligible people
Systemic sclerosis is a condition that leads to skin and organ hardening. UCSF is conducting research on the effectiveness of vixarelimab for lung issues related to this disease. Another study is focused on the impact and safety of a treatment called rapcabtagene autoleucel.
Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
open to eligible people ages 18-85
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease …
Fresno, California and other locations
Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
open to eligible people ages 18-65
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to…
San Francisco, California and other locations
Our lead scientists for Systemic Sclerosis research studies include Emily Von Scheven.
Last updated: